JPRN-UMIN000015105
Completed
Phase 2
A randomized phase 2 trial which investigate the most effective administration method of antithrombin (AT) products in patients with disseminated intravascular coagulation (DIC) associated with sepsis during treatment for advanced pancreatic and biliary cancer. - A randomized phase 2 trial of AT-III products in infectious DIC.
Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology0 sites40 target enrollmentSeptember 10, 2014
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- advanced hepatobiliary and pancreatic cancer patients
- Sponsor
- Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •pregnat or possible pregnat women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancerMetastatic breast cancerJPRN-UMIN000027382Kyushu Breast Cancer Study Group (KBC-SG)90
Suspended
Phase 2
A phase II randomized clinical trial to determine the effectiveness of goreisan and saireito for lower limb lymphedema in women treated for gynecologic cancerower Limb LymphedemaLymphedemaD008209JPRN-jRCT1041190019Kajiyama Hiroaki40
Active, not recruiting
Phase 1
A trial examining the effects of alteplase in patients with severe respiratory failure.EUCTR2010-024377-40-ATMedizinische Universität Wien, UniKlinik für Klinische Pharmakologie
Completed
Phase 2
Efficacy of a new COVID-19 treatmentPACTR202006899597082Malagasy government60
Active, not recruiting
Phase 1
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62